Efficacy and safety of immune checkpoint blockade in self-identified Black patients with advanced non-small cell lung cancer.

Real-world analysis of the authors' institutional experience demonstrated similar efficacy and tolerability of ICB in Black versus White patients with advanced NSCLC. Larger multi-institutional studies including other US minority populations would make the findings of the current study more generalizable.